Until now, the clinical significance of the Ars2 gene expression has not been explored in AML, nor have the mechanistic details of Ars2’s role in the regulation of miRNA biogenesis and leukemogenesis in AML been evaluated in depth. The gene discussed is SRRT; the disease is acute myeloid leukemia.